Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface

Simon O. Clark, Giovanni Delogu, Emma Rayner, Michela Sali, Ann Williams, Riccardo Manganelli

Research output: Contribution to journalArticle

Abstract

The lack of an efficient vaccine against tuberculosis is still one of the major problems threatening global human health. In previous work we showed that expression of the protective antigen MPT64 on the surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved its immunogenicity and protective potential in mice. In this work we demonstrate that the same recombinant strain is able to induce better protection than wild type BCG also in guinea pigs preventing Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for further testing.

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalTrials in Vaccinology
Volume4
DOIs
Publication statusPublished - 2015

Fingerprint

Mycobacterium bovis
Tuberculosis Vaccines
Guinea Pigs
Vaccination
Mycobacterium tuberculosis
Pathology
Antigens
Lung

Keywords

  • Animal model
  • Guinea pigs
  • Tuberculosis
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health

Cite this

Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface. / Clark, Simon O.; Delogu, Giovanni; Rayner, Emma; Sali, Michela; Williams, Ann; Manganelli, Riccardo.

In: Trials in Vaccinology, Vol. 4, 2015, p. 29-32.

Research output: Contribution to journalArticle

Clark, Simon O. ; Delogu, Giovanni ; Rayner, Emma ; Sali, Michela ; Williams, Ann ; Manganelli, Riccardo. / Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface. In: Trials in Vaccinology. 2015 ; Vol. 4. pp. 29-32.
@article{c0b6cdaf24fc470bafc60ab69e763a0f,
title = "Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface",
abstract = "The lack of an efficient vaccine against tuberculosis is still one of the major problems threatening global human health. In previous work we showed that expression of the protective antigen MPT64 on the surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved its immunogenicity and protective potential in mice. In this work we demonstrate that the same recombinant strain is able to induce better protection than wild type BCG also in guinea pigs preventing Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for further testing.",
keywords = "Animal model, Guinea pigs, Tuberculosis, Vaccines",
author = "Clark, {Simon O.} and Giovanni Delogu and Emma Rayner and Michela Sali and Ann Williams and Riccardo Manganelli",
year = "2015",
doi = "10.1016/j.trivac.2015.03.003",
language = "English",
volume = "4",
pages = "29--32",
journal = "Trials in Vaccinology",
issn = "1879-4378",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface

AU - Clark, Simon O.

AU - Delogu, Giovanni

AU - Rayner, Emma

AU - Sali, Michela

AU - Williams, Ann

AU - Manganelli, Riccardo

PY - 2015

Y1 - 2015

N2 - The lack of an efficient vaccine against tuberculosis is still one of the major problems threatening global human health. In previous work we showed that expression of the protective antigen MPT64 on the surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved its immunogenicity and protective potential in mice. In this work we demonstrate that the same recombinant strain is able to induce better protection than wild type BCG also in guinea pigs preventing Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for further testing.

AB - The lack of an efficient vaccine against tuberculosis is still one of the major problems threatening global human health. In previous work we showed that expression of the protective antigen MPT64 on the surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved its immunogenicity and protective potential in mice. In this work we demonstrate that the same recombinant strain is able to induce better protection than wild type BCG also in guinea pigs preventing Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for further testing.

KW - Animal model

KW - Guinea pigs

KW - Tuberculosis

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84927915100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927915100&partnerID=8YFLogxK

U2 - 10.1016/j.trivac.2015.03.003

DO - 10.1016/j.trivac.2015.03.003

M3 - Article

VL - 4

SP - 29

EP - 32

JO - Trials in Vaccinology

JF - Trials in Vaccinology

SN - 1879-4378

ER -